{
    "id": 26673,
    "fullName": "AFAP1 - NTRK2",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "AFAP1-NTRK2 results from the fusion of AFAP and NTRK2, which leads to increased Erk phosphorylation and is transforming in cultured cells (PMID: 28512244). AFAP1-NTRK2 has been identified in low grade gliomas (PMID: 28512244).",
            "references": [
                {
                    "id": 9257,
                    "pubMedId": 28512244,
                    "title": "Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28512244"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 60312,
        "geneSymbol": "AFAP1",
        "terms": [
            "AFAP1",
            "AFAP",
            "AFAP-110",
            "AFAP110"
        ]
    },
    "variant": "AFAP1 - NTRK2",
    "createDate": "07/03/2017",
    "updateDate": "10/18/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4915,
                "geneSymbol": "NTRK2",
                "terms": [
                    "NTRK2",
                    "EIEE58",
                    "GP145-TrkB",
                    "OBHD",
                    "trk-B",
                    "TRKB"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11364,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing AFAP1-NTRK2 demonstrated sensitivity to Rozlytrek (entrectinib) in culture (PMID: 28512244).",
            "molecularProfile": {
                "id": 27968,
                "profileName": "AFAP1 - NTRK2"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9257,
                    "pubMedId": 28512244,
                    "title": "Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28512244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15724,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing AFAP1-NTRK2 were sensitive to Rozlytrek (entrectinib) as demonstrated by reduced proliferation relative to cells expressing an empty vector in culture (PMID: 26884591).",
            "molecularProfile": {
                "id": 27968,
                "profileName": "AFAP1 - NTRK2"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6326,
                    "pubMedId": 26884591,
                    "title": "What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884591"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27968,
            "profileName": "AFAP1 - NTRK2",
            "profileTreatmentApproaches": [
                {
                    "id": 19321,
                    "name": "Larotrectinib",
                    "profileName": "AFAP1 - NTRK2"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}